ArticleGastrointestinal cancer research : GCR2008
Targeted therapies for pancreatic cancer.
Article in Gastrointestinal cancer research : GCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging.Annals of surgical oncology · 2018Article
- A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model.OncoTargets and therapy · 2018Article
- EMT and Treatment Resistance in Pancreatic Cancer.Cancers · 2017Review
- Protein kinase D signaling in cancer: A friend or foe?Biochimica et biophysica acta. Reviews on cancer · 2017Review
- Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancer.Bioorganic & medicinal chemistry letters · 2016Article
- Potential effects of Mina53 on tumor growth in human pancreatic cancer.Cell biochemistry and biophysics · 2014Article
- Pancreatic cancer.British journal of pharmacology · 2014Review
- The VEGF pathway in cancer and disease: responses, resistance, and the path forward.Cold Spring Harbor perspectives in medicine · 2012Review
- Protein kinase D as a potential new target for cancer therapy.Biochimica et biophysica acta · 2010Review
- Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.Neoplasia (New York, N.Y.) · 2010Article
- Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src.The Journal of pharmacology and experimental therapeutics · 2010Article
- Tumor biology and cancer therapy - an evolving relationship.Cell communication and signaling : CCS · 2009Article
- The burning question: why is smoking a risk factor for pancreatic cancer?Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]Review
- The Diverse Involvement of Cigarette Smoking in Pancreatic Cancer Development and Prognosis.PancreasReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis of patients with pancreatic cancer is extremely poor, and current systemic therapies provide marginal survival benefits for treated patients. The era of targeted therapies has offered a new avenue to search for potentially more effective strategies. Findings from phase III studies of molecular agents targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) were disappointing, although results with the EGFR tyrosine kinase inhibitor erlotinib were statistically significant but clinically of marginal benefit. Ongoing trials are assessing other single targeted agents and combinations of targeted therapies combined with gemcitabine in an effort to treat the multiple molecular pathways that seem to be active in this disease. Better preclinical modeling, improved clinical trial designs with adequate pilot studies, and better patient selection in trials of interventions are needed to improve the yield from research efforts.
Identifiers
19343141PMC2661543W2416669648What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.